FIELD: biotechnology.
SUBSTANCE: invention relates to a bispecific fused polypeptide, and can be used in medicine.
EFFECT: fused polypeptide comprising a finer sequence which binds to interleukin-17A (IL-17a) and is conjugated with an antibody bound to an interleukin-6 (IL-6R) receptor, inhibits both IL-17a and IL-6R activity and can be effectively used in therapy of rheumatoid arthritis, psoriasis, arthritis and uveitis.
2 cl, 29 dwg, 28 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL IL-17-BINDING COMPOUNDS AND THEIR MEDICINAL APPLICATION | 2010 |
|
RU2550272C2 |
| NUCLEOTIDE SEQUENCE CODING FUSION PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN IL-6R AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IGG4 | 2023 |
|
RU2818329C1 |
| ADVANCED ANTIBODY MOLECULES | 2009 |
|
RU2430111C1 |
| POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5 | 2013 |
|
RU2654668C2 |
| ANTIBODY OR ITS ANTI-BINDING FRAGMENT, WHICH IS CAPABLE TO BE BOUND USING THE INTERLEUKIN-6 HUMAN RECEPTOR | 2016 |
|
RU2656160C2 |
| PHARMACEUTICAL FORMULATION CONTAINING ADVANCED ANTIBODY MOLECULES | 2010 |
|
RU2565809C2 |
| IMPROVED AMINO ACID SEQUENCES AGAINST IL-6R AND POLYPEPTIDES WHICH CONTAIN THEREOF FOR TREATMENT OF IL-6R ASSOCIATED DISEASES AND DISORDERS | 2010 |
|
RU2539798C2 |
| IMPROVED PHARMACOKINETIC ASSAYS FOR SINGLE VARIABLE IMMUNOGLOBULIN DOMAINS | 2017 |
|
RU2765809C2 |
| FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
| TRISPECIFIC IL-17A, IL-17F AND OTHER PROINFLAMMATORY MOLECULES ANTIBODIES | 2016 |
|
RU2680011C2 |
